172 related articles for article (PubMed ID: 15026413)
21. Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila.
Auluck PK; Meulener MC; Bonini NM
J Biol Chem; 2005 Jan; 280(4):2873-8. PubMed ID: 15556931
[TBL] [Abstract][Full Text] [Related]
22. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein.
Okochi M; Walter J; Koyama A; Nakajo S; Baba M; Iwatsubo T; Meijer L; Kahle PJ; Haass C
J Biol Chem; 2000 Jan; 275(1):390-7. PubMed ID: 10617630
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease and other alpha-synucleinopathies.
Goedert M
Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
[TBL] [Abstract][Full Text] [Related]
24. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125.
Nakamura T; Yamashita H; Takahashi T; Nakamura S
Biochem Biophys Res Commun; 2001 Feb; 280(4):1085-92. PubMed ID: 11162638
[TBL] [Abstract][Full Text] [Related]
25. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
Windisch M; Hutter-Paier B; Rockenstein E; Hashimoto M; Mallory M; Masliah E
J Mol Neurosci; 2002; 19(1-2):63-9. PubMed ID: 12212795
[TBL] [Abstract][Full Text] [Related]
26. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
[TBL] [Abstract][Full Text] [Related]
27. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944
[TBL] [Abstract][Full Text] [Related]
28. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
Iwatsubo T
Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
[TBL] [Abstract][Full Text] [Related]
29. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Braithwaite SP; Stock JB; Mouradian MM
Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
[TBL] [Abstract][Full Text] [Related]
30. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS.
Li J-; Henning Jensen P; Dahlström A
Neuroscience; 2002; 113(2):463-78. PubMed ID: 12127102
[TBL] [Abstract][Full Text] [Related]
31. Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation.
Lee G; Tanaka M; Park K; Lee SS; Kim YM; Junn E; Lee SH; Mouradian MM
J Biol Chem; 2004 Feb; 279(8):6834-9. PubMed ID: 14645218
[TBL] [Abstract][Full Text] [Related]
32. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.
Bayer TA; Jäkälä P; Hartmann T; Havas L; McLean C; Culvenor JG; Li QX; Masters CL; Falkai P; Beyreuther K
Neurosci Lett; 1999 May; 266(3):213-6. PubMed ID: 10465711
[TBL] [Abstract][Full Text] [Related]
33. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.
Galvin JE; Uryu K; Lee VM; Trojanowski JQ
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13450-5. PubMed ID: 10557341
[TBL] [Abstract][Full Text] [Related]
34. O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease.
Wani WY; Ouyang X; Benavides GA; Redmann M; Cofield SS; Shacka JJ; Chatham JC; Darley-Usmar V; Zhang J
Mol Brain; 2017 Jul; 10(1):32. PubMed ID: 28724388
[TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.
Biere AL; Wood SJ; Wypych J; Steavenson S; Jiang Y; Anafi D; Jacobsen FW; Jarosinski MA; Wu GM; Louis JC; Martin F; Narhi LO; Citron M
J Biol Chem; 2000 Nov; 275(44):34574-9. PubMed ID: 10942772
[TBL] [Abstract][Full Text] [Related]
36. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
Krüger R; Müller T; Riess O
J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
[TBL] [Abstract][Full Text] [Related]
37. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease.
Tabner BJ; Turnbull S; El-Agnaf OM; Allsop D
Free Radic Biol Med; 2002 Jun; 32(11):1076-83. PubMed ID: 12031892
[TBL] [Abstract][Full Text] [Related]
38. The cellular pathology of Parkinson's disease.
Takahashi H; Wakabayashi K
Neuropathology; 2001 Dec; 21(4):315-22. PubMed ID: 11837539
[TBL] [Abstract][Full Text] [Related]
39. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
Norris EH; Giasson BI
Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012
[TBL] [Abstract][Full Text] [Related]
40. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
